Neil Josephson

Insider

First SEC filing: Dec. 23, 2022 · Latest: Dec. 23, 2022

On this page

Insider at

0 buys (P) 0 sells (S) Net: $0 + 4 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

4 other filings hidden

Date	Ticker	Code	Shares	Price	Value	Owned after	Δ own	A/D	vs now
Nov. 10, 2022	ZYME	M	5,885	—	—	11,772 Direct	-33.33%	Disposed	(price as of 2026-08-20)
Nov. 10, 2022	ZYME	S 10b5-1	2,475	$8.10	$20,048	14,449 Direct	-14.62%	Disposed	229.3% (price as of 2026-08-20)
Nov. 10, 2022	ZYME	M	5,885	—	—	16,924 Direct	+53.31%	Acquired	(price as of 2026-08-20)
Nov. 10, 2022	ZYME	M	5,885	—	—	11,772 Direct	-33.33%	Disposed	(price as of 2026-08-20)
Nov. 10, 2022	ZYME	S 10b5-1	2,475	$8.10	$20,048	14,449 Direct	-14.62%	Disposed	229.3% (price as of 2026-08-20)
Nov. 10, 2022	ZYME	M	5,885	—	—	16,924 Direct	+53.31%	Acquired	(price as of 2026-08-20)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Options, RSUs and convertible securities reported on Form 4 Table II.

Date	Ticker	Security	Underlying	Exercise price	Expiration	Shares	A/D
Nov. 10, 2022	ZYME	Restricted Stock Unit	Common Shares (5,885)	—	—	5,885	Disposed
Nov. 10, 2022	ZYME	Restricted Stock Unit	Common Shares (5,885)	—	—	5,885	Disposed

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Matched by name from proxy statements (DEF 14A) — verify against the filing.

Chief Medical Officer (10)

Fiscal year	Salary	Bonus	Stock awards	Option awards	Non-equity incentive	Pension change	Other	Total
2021	$456,653	—	—	—	—	—	$17,438	$3,547,690

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.